Blue Water Acquisition III - Unit. (BLUWU) vs Outlook Therapeutics (OTLK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Blue Water Acquisition III - Unit. (BLUWU) has outperformed Outlook Therapeutics (OTLK) over the past year, gaining 4.7% versus a loss of 55.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLUWU | OTLK |
|---|---|---|
| Share price | $10.50 | $0.564 |
| Market cap | — | $137.30M |
| 1-day change | 0.00% | -4.41% |
| YTD return | -0.47% | -64.30% |
| 1-year return | +4.69% | -55.24% |
| 5-year return | — | -98.66% |
| EPS (TTM) | — | $-0.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.85 | $2.54 |
| 52-week low | $10.03 | $0.161 |
| Distance from 52-week high | -18.29% | -77.78% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +791.84% |
| Average volume | 48 | 13.33M |
| Shares outstanding | — | 243.45M |
| Employees | — | 17 |
| Sector | Financial Services | Health Care |
| Industry | Shell Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BLUWU has outperformed OTLK by 59.9 percentage points over the past year.
- The two companies sit in different sectors: Blue Water Acquisition III - Unit. in Financial Services and Outlook Therapeutics in Health Care.
About Blue Water Acquisition III - Unit.
BLUWU stock →Blue Water Acquisition Corp. III does not have significant operations.
Financial Services · Shell Companies
About Outlook Therapeutics
OTLK stock →Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees
BLUWU vs OTLK FAQ
Which stock has performed better over the past year, BLUWU or OTLK?
BLUWU returned +4.69% over the past 12 months, compared with -55.24% for OTLK (price return, excluding dividends). Past performance does not predict future results.
Are Blue Water Acquisition III - Unit. and Outlook Therapeutics in the same industry?
No. Blue Water Acquisition III - Unit. is in the Financial Services sector, while Outlook Therapeutics is in Health Care.